Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver

被引:65
作者
Owen, A
Goldring, C
Morgan, P
Chadwick, D
Park, BK
Pirmohamed, M
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
[2] Univ Liverpool, Dept Neurol Sci, Liverpool L69 3GE, Merseyside, England
[3] Pfizer Ltd, Global Res & Dev, Dept Drug Metab, Sandwich CT13 9NJ, Kent, England
关键词
ABCB1; C3435T; expression; G2677T/; A; MDR1; P-glycoprotein; SNP;
D O I
10.1111/j.1365-2125.2005.02229.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims The aim of the study was to determine whether a correlation exists between MDR1 (ABCB1) gene polymorphisms at positions 3435 (C3435T) and 2677 (G(2677)T(A)) and the expression of human hepatic P-glycoprotein (P-gp). Methods P-gp protein expression in 26 human livers was assessed by Western blotting and ABCB1 mRNA expression was determined by real time RT-PCR. The C3435T and G(2677)T(A) polymorphisms were identified by RFLP and direct sequence analysis, respectively. Results The C and G allele frequencies for the C3435T and G(2677)T(A) polymorphisms were 0.48 and 0.79, respectively, and the genotypes were in Hardy-Weinberg equilibrium. There was a 200- and 20-fold variation in the expression of ABCB1 mRNA and Pgp protein expression, respectively. There were no differences in mRNA and protein expression identified amongst the different genotypes attributable to the C3435T and G(2677)T(A) polymorphisms in the ABCB1 gene. Exposure to a PXR ligand prior to death did not influence mRNA or protein expression. Conclusions There is substantial variability in the expression of Pgp in human liver, but this is not due to the presence of C3435T and G(2677)T(A) polymorphisms in the ABCB1 gene, although our study is limited by a small sample size.
引用
收藏
页码:365 / 370
页数:6
相关论文
共 32 条
[1]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[2]  
Brinkmann U, 2002, NOVART FDN SYMP, V243, P231
[3]  
Brinkmann U, 2002, NOVART FDN SYMP, V243, P210
[4]  
Brinkmann Ulrich, 2002, Novartis Found Symp, V243, P207
[5]  
Calado RT, 2002, HAEMATOLOGICA, V87, P564
[6]   Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects [J].
Cascorbi, I ;
Gerloff, T ;
Johne, A ;
Meisel, C ;
Hoffmeyer, S ;
Schwab, M ;
Schaeffeler, E ;
Eichelbaum, M ;
Brinkmann, U ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :169-174
[7]   MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine [J].
Drescher, S ;
Schaeffeler, E ;
Hitzl, M ;
Hofmann, U ;
Schwab, M ;
Brinkmann, U ;
Eichelbaum, M ;
Fromm, MF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (05) :526-534
[8]  
El-Sankary W, 2000, DRUG METAB DISPOS, V28, P493
[9]   Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease [J].
Furuno, T ;
Landi, MT ;
Ceroni, M ;
Caporaso, N ;
Bernucci, I ;
Nappi, G ;
Martignoni, E ;
Schaeffeler, E ;
Eichelbaum, M ;
Schwab, M ;
Zanger, UM .
PHARMACOGENETICS, 2002, 12 (07) :529-534
[10]   The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells [J].
Hitzl, M ;
Drescher, S ;
van der Kuip, H ;
Schäffeler, E ;
Fischer, J ;
Schwab, M ;
Eichelbaum, M ;
Fromm, MF .
PHARMACOGENETICS, 2001, 11 (04) :293-298